Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2020
2019
Profitability Metrics
Gross Margin
118.00%
Operating Margin
35.44%
Net Margin
20.59%
Efficiency Metrics
Revenue per Expense Ratio
1.55
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
30.55%
Income Tax Rate
21.58%
EPS
2.4500000000
Balance Sheet Analysis
Current Ratio
0.03
Cash Ratio
-0.63
Working Capital
$-5.89B
Debt to Equity
0.48
Debt to Assets
5.16%
Equity Ratio
10.86%
Cash Flow Analysis
Operating Cash Flow Ratio
35.65%
Free Cash Flow Ratio
32.75%
CapEx to Revenue
2.90%
Dividends Paid
$95.10M
Stock Buybacks
$30.23M
Total Shareholder Returns
$125.34M
Cash Position Change
-9.02%
Key Takeaways (2023 FY)
Revenue declined by 5.6937830736507%, indicating potential market challenges
Increased dividend payments by 2.40%
Detailed Growth Metrics
Core Performance
Revenue
-5.69%
Net Income
-29.86%
EPS
-29.60%
Operating Income
-18.50%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
60.72%
Operating Cash Flow
6.44%
Free Cash Flow
4.04%
Balance Sheet Health
Assets
-1.77%
Debt
-75.84%
Book Value per Share
10.03%
Inventory
100.00%
Shareholder Returns
Dividends per Share
2.40%
Shares Outstanding
-0.55%
Long Term Trends
3Y Revenue/Share
6.16%
5Y Revenue/Share
7.40%
3Y Dividend/Share
7.86%
5Y Dividend/Share
26.97%